Asociatia Oncohelp

Futó vizsgálatok

• Toboroz

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· 3. fázis· Forrás

• Toboroz

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· 2. fázis· Forrás

• Toboroz

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· 3. fázis· Forrás

• Meghívásos bevonás

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· 2. fázis· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· 3. fázis· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· 3. fázis· Forrás

• Toboroz

  A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting

  2025-521919-39-00· 1. fázis· Forrás

• Toboroz

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· 3. fázis· Forrás

• Toboroz

  Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

  NCT07246863· 2. fázis· Forrás

• Toboroz

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Forrás

• Toboroz

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· 3. fázis· Forrás

• Toboroz

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· 2. fázis· Forrás

• Toboroz

  LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.

  2022-501315-13-00· 3. fázis· Forrás

• Toboroz

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· 2. fázis· Forrás

• Toboroz

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· 2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· 3. fázis· Forrás

• Fut, nem toboroz

  Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06290934· 2. fázis· Forrás

• Toboroz

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák5 toboroz
• Crohn-betegség4 toboroz
• Colitis ulcerosa3 toboroz
• Áttétes emlőrák2 toboroz
• Fej-nyaki daganatok1 toboroz
• Melanóma1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· 2. fázis· Forrás